Bone Marrow Edema – Causes, Symptoms & Treatment

What Is Bone Marrow Edema?

Bone marrow edema (BME) refers to an abnormal accumulation of fluid within the interior of a bone, specifically in the bone marrow. Unlike external swelling visible to the naked eye, bone marrow edema cannot be detected by physical examination alone. It is diagnosed primarily through magnetic resonance imaging (MRI), where it appears as a characteristic bright signal in T2-weighted sequences.

Bone marrow edema is not a standalone disease but a radiological finding that can indicate a range of underlying conditions. It most commonly affects weight-bearing joints such as the knee, hip and ankle. Patients typically describe a deep, dull aching pain within the bone that worsens with physical activity and tends to persist during rest.

Causes

The causes of bone marrow edema are diverse. A distinction is made between primary (idiopathic) and secondary forms, which occur as a consequence of another underlying condition.

Common Causes

• Trauma: Contusions, falls, fractures or stress fractures can lead to localized fluid accumulation within the bone.
• Osteoarthritis: Bone marrow edema frequently accompanies advanced joint degeneration and often correlates with pain intensity.
• Circulatory disorders: Impaired microcirculation in the bone can lead to transient osteoporosis, a condition characterized by pronounced bone marrow edema, particularly in the hip.
• Inflammatory joint diseases: Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis can all cause bone marrow edema as a marker of active inflammation.
• Avascular necrosis: Interruption of blood supply to the bone can result in bone marrow edema as an early sign, potentially preceding actual bone cell death.
• Idiopathic bone marrow edema: In some cases no identifiable cause is found. This form occurs more frequently in middle-aged men and often resolves spontaneously.

Symptoms

The hallmark symptom is a deep, often throbbing or aching bone pain that typically:

• increases with weight-bearing activity,
• subsides slowly during rest,
• is associated with local tenderness on palpation,
• may be accompanied by mild swelling of the affected joint.

Depending on the extent and location, bone marrow edema can significantly limit joint mobility and reduce overall quality of life.

Diagnosis

The diagnosis of bone marrow edema is established primarily through MRI. The edema appears as a hyperintense (bright) zone within the bone on T2-weighted or fat-suppressed sequences. Conventional X-rays and computed tomography (CT) are generally unable to visualize the edema directly but can be used to identify bony structural changes or rule out fractures.

Blood tests including inflammatory markers and rheumatological panels may help identify underlying inflammatory causes.

Treatment

Treatment depends on the underlying cause, the severity of symptoms and the individual patient. No single universal standard treatment exists.

Conservative Management

• Rest and offloading: Reducing mechanical load on the affected joint, often with the use of crutches.
• Physiotherapy: Targeted exercises to improve local circulation and stabilize the joint.
• Pain management: Non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation control.
• Iloprost infusion therapy: A prostacyclin analogue shown in controlled studies to improve microcirculation and reduce bone marrow edema, particularly in severe cases.
• Bisphosphonate therapy: Drugs such as alendronate can regulate bone remodeling and have demonstrated efficacy in clinical studies.

A well-balanced diet that includes nutrients supporting joint and bone health can play a complementary role during recovery. Our Joint Complex with UC-II collagen provides targeted nutritional support for joints and cartilage.

Surgical Options

• Core decompression: In severe cases, particularly those associated with avascular necrosis, drilling into the bone can relieve intraosseous pressure and restore blood flow.
• Arthroscopy: May be indicated when concurrent intra-articular pathologies are present.

Course and Prognosis

The clinical course is variable. Idiopathic bone marrow edema frequently resolves spontaneously within three to twelve months. Secondary forms, such as those associated with osteoarthritis or inflammatory disease, may follow a chronic course and require longer-term management. Early diagnosis and consistent treatment significantly improve the prognosis.

Supporting joint health during and after recovery can be an important part of long-term management. Our Joint Complex with native type II collagen (UC-II) was specifically formulated to support joint and cartilage health.

Prevention

Complete prevention is not always possible, but the following measures may reduce the risk:

• Joint-friendly physical activity such as swimming or cycling,
• avoiding overuse injuries and high-impact trauma,
• adequate intake of calcium, vitamin D and other bone-relevant nutrients,
• consistent treatment of underlying conditions such as rheumatoid arthritis or osteoarthritis.

Those looking to support their joint health over the long term may find our Joint Complex with UC-II, hyaluronic acid and further active ingredients a thoughtfully formulated addition to their daily routine.

Frequently Asked Questions

How long does bone marrow edema last?

The duration varies considerably. Idiopathic bone marrow edema often resolves spontaneously within three to twelve months. Secondary forms related to conditions such as osteoarthritis or inflammatory joint disease may persist much longer and depend heavily on the treatment of the underlying cause. Early diagnosis and appropriate therapy can accelerate recovery.

Is bone marrow edema dangerous?

Bone marrow edema is generally not life-threatening but can cause significant pain and functional limitations. In untreated or severe cases, particularly those linked to avascular necrosis, there is a risk of permanent bone damage. Timely evaluation by a specialist is therefore important to prevent long-term complications.

What pain relief is available for bone marrow edema?

Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or diclofenac are commonly used for pain management. In more severe cases, iloprost infusions or bisphosphonates may be prescribed. The choice of treatment should always be made in consultation with a physician, taking into account individual health factors and potential interactions.

Can you exercise with bone marrow edema?

During the acute phase, significant reduction in joint loading is recommended to support healing. Low-impact activities such as swimming or cycling are often better tolerated. High-impact sports, running and jumping activities should be avoided until the edema has fully resolved. Individual guidance from a treating physician or physiotherapist is strongly recommended.

How is bone marrow edema diagnosed?

MRI is the gold standard for diagnosing bone marrow edema. It provides precise visualization of the fluid accumulation and the affected bone regions. Standard X-rays and CT scans are not suitable for direct visualization of the edema but can complement the diagnosis by assessing bony structures or ruling out fractures. Blood tests may provide additional evidence for inflammatory causes.

What is the difference between bone marrow edema and avascular necrosis?

Bone marrow edema refers to a reversible fluid accumulation within the bone marrow. Avascular necrosis, by contrast, describes the death of bone tissue resulting from interrupted blood supply and represents a more serious condition. Bone marrow edema can be an early sign or precursor to avascular necrosis and should therefore be investigated and monitored carefully.

References

1. Hofmann S, Kramer J, Vakil-Adli A, et al. Bone marrow edema syndrome of the knee: treatment with iloprost. Orthopade. 2006;35(1):84-92.
2. Korompilias AV, Karantanas AH, Lykissas MG, Beris AE. Bone marrow edema syndrome. Skeletal Radiology. 2009;38(5):425-436.
3. Eriksen EF. Treatment of bone marrow lesions (bone marrow edema). BoneKEy Reports. 2015;4:755.